Genfleet Therapeutics (Shanghai) Co. Ltd. has divulged new phosphatidylinositol 3-kinase (PI3K) inhibitors potentially useful for the treatment of cancer, Alzheimer’s disease, aging, diabetes, Parkinson’s disease, asthma, cardiovascular disease and allergy, among others.